Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment

Anxiety and Depression

Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study

Eur Neuropsychopharmacol.

Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J, Montgomery S, Zohar J, Kasper S

doi: 10.1016/j.euroneuro.

Anxiety and Depression

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

J Clin Psychiatry.

Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB

doi: 10.4088/JCP.19m12891.

Anxiety and Depression

Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance

World J Biol Psychiatry

Kasper S, Cubała WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young AH

doi: 10.1080/15622975.2020.1836399

Anxiety and Depression

Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant

J Affect Disord

Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, Drevets WC, Cooper K, Lane R, Singh J

doi: 10.1016/j.jad.2020.11.066

Anxiety and Depression

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

Int J Neuropsychopharmacol.

Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM

doi: 10.1093/ijnp/pyaa068.

RECOMMENDED

Anxiety and Depression

Psychotic features in patients with major depressive disorder: A report from the European Group for the Study of Resistant Depression

J Clin Psychiatry.

Dold M, Bartova L, Kautzky A, Porcelli S, Montgomery S, Zohar J, Mendlewicz J, Souery D, Serretti A, Kasper S

doi: 10.4088/JCP.17m12090.

Anxiety and Depression

Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression

Depress Anxiety

Bartova L, Dold M, Fugger G, Kautzky A, Mitschek MMM, Weidenauer A, Hienert MG, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S

doi: 10.1002/da.23165

Bipolar Disorder

Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition

Br J Psychiatry.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA

doi: 10.1192/bjp.2018.257.

RECOMMENDED

Anxiety and Depression

High occupational level is associated with poor response to the treatment of depression: A replication study

Eur Neuropsychopharmacol.

Mandelli L, Serretti A, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J

doi: 10.1016/j.euroneuro.

Related content

Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

Psychotic features in patients with major depressive disorder: A report from the European Group for the Study of Resistant Depression

Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression

Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition

High occupational level is associated with poor response to the treatment of depression: A replication study